Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of Tulisokibart (MK-7240) in Healthy Chinese Participants
NCT06829225Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2024
- Primary completion
- Nov 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of tulisokibart in ulcerative colitis (UC) (6 arms), sponsored by Merck & Co. Primary endpoints: Number of Participants Who Experience an Adverse Event (AE) up to 99 days, Number of Participants Who Discontinued the Study Due to AEs up to 99 days and 7 more. Started Jun 2024; status: completed.
02
Drugs
tulisokibart
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT06829225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06829225.